Fractionated Stereotactic Sequential Boost in a Selected Cohort of Glioblastoma Patients: A Mono-institutional Analysis

Anticancer Res. 2020 Jun;40(6):3387-3393. doi: 10.21873/anticanres.14322.


Aim: To retrospectively assess toxicity and survival in 15 selected Glioblastoma patients treated with a sequential fractionated stereotactic radiotherapy (FSRT) boost after chemo-radiotherapy (CHT-RT) and compare their survival outcomes with a control group.

Patients and methods: Toxicity was assessed with the CTCAE 3.0 scale. The Kaplan-Meier method was used to design survival curves, log-rank test for bivariate analysis and Cox proportional hazard regression model for multivariate analysis.

Results: The median follow-up was 16 months (range=5-60). One case of headache and one of radionecrosis (RN) occurred. Median overall survival (OS) was 25 months in the boost group vs. 14 in the no-boost group (p=0.004). Median progression-free survival (PFS) was 15 months in the boost group versus 8 in the no-boost group (p=0.046). At multivariate analysis FSRT boost resulted significantly associated with OS and PFS.

Conclusion: In our series a sequential FSRT boost resulted in safe outcomes and significantly associated with survival.

Keywords: Glioblastoma; boost; fractionated stereotactic radiotherapy; survival; toxicity.

MeSH terms

  • Adult
  • Aged
  • Brain Neoplasms / diagnosis
  • Brain Neoplasms / mortality
  • Brain Neoplasms / radiotherapy*
  • Cohort Studies
  • Dose Fractionation, Radiation*
  • Female
  • Glioblastoma / diagnosis
  • Glioblastoma / mortality
  • Glioblastoma / radiotherapy*
  • Humans
  • Kaplan-Meier Estimate
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Radiosurgery* / methods
  • Radiotherapy Planning, Computer-Assisted
  • Radiotherapy, Image-Guided
  • Tomography, X-Ray Computed
  • Treatment Outcome